{"mainPropery":{"diseaseId":9396,"diseaseName":"Fibrolamellar carcinoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9396/fibrolamellar-carcinoma","synonyms":["Fibrolamellar variant of hepatocellular carcinoma","Hepatocellular carcinoma (fibrolamellar variant)","Fibrolamellar hepatocellular carcinoma","Eosinophilic hepatocellular carcinoma with lamellar fibrosis","Polygonal cell hepatocellular carcinoma with fibrous stroma","Hepatocellular carcinoma with increased stromal fibrosis","Eosinophilic glassy cell hepatoma","Fibrolamellar oncocytic hepatoma","FL-HCC","FHCC","Fibrolamellar hepatocarcinoma"],"synonyms-with-source":[{"name":"Fibrolamellar variant of hepatocellular carcinoma"},{"name":"Hepatocellular carcinoma (fibrolamellar variant)"},{"name":"Fibrolamellar hepatocellular carcinoma","source":""},{"name":"Eosinophilic hepatocellular carcinoma with lamellar fibrosis"},{"name":"Polygonal cell hepatocellular carcinoma with fibrous stroma"},{"name":"Hepatocellular carcinoma with increased stromal fibrosis"},{"name":"Eosinophilic glassy cell hepatoma"},{"name":"Fibrolamellar oncocytic hepatoma"},{"name":"FL-HCC","source":""},{"name":"FHCC","source":"OrphaData.Org"},{"name":"Fibrolamellar hepatocarcinoma","source":"OrphaData.Org"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"401920"},{"identifierType":"UMLS","identifierId":"C0334287"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":862,"resourceName":"Fibrolamellar Cancer Foundation","address1":"20 Horseneck Lane, 2nd Floor","address2":"","address3":"","address4":"","address5":"","city":"Greenwich","state":"CT","zip":"06830","country":"United States","phone":"203-862-3196","tty":"","tollFree":"","fax":"","email":"lomalley@fibrofoundation.org","url":"http://www.fibrofoundation.org/"},{"resourceID":942,"resourceName":"American Association for the Study of Liver Diseases","abbreviation":"","address1":"1001 North Fairfax, 4th floor","address2":"","address3":"","address4":"","address5":"","city":"Alexandria","state":"VA","zip":"22314","country":"United States","phone":"703–299–9766","tty":"","tollFree":"","fax":"703–299–9622","email":"aasld@aasld.org","url":"http://www.aasld.org/","freeText":""},{"resourceID":943,"resourceName":"American Liver Foundation","abbreviation":"","address1":"39 Broadway, Suite 2700","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10006","country":"United States","phone":"+1-212-668-1000","tty":"","tollFree":"+1-800-465-4837 (Helpline)","fax":"","email":"https://liverfoundation.org/for-patients/contact-us/","url":"https://liverfoundation.org/","freeText":""},{"resourceID":3585,"resourceName":"The Max Burdette Fibrolamellar Cancer Research Foundation","abbreviation":"","address1":"9056 Stone Walk Place ","address2":"Ste 246 ","address3":"","address4":"","address5":"","city":"Germantown","state":"TN","zip":"38138","country":"United States","phone":"(901) 842-9234","tty":"","tollFree":"","fax":"","email":"christina@maxburdette.com","url":"http://www.maxburdette.com/threecolumn.html","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=Fibrolamellar%20hepatocellular%20carcinoma%5BTIAB%5D%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Fibrolamellar carcinoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Hepatocellular+carcinoma+(fibrolamellar+variant)%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Fibrolamellar carcinoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":710,"resourceId":1405,"resourceName":"NIDDK - Hepatocellular carcinoma","descriptionText":"The National Institute of Diabetes and Digestive and Kidney Diseases, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, Department of Veteran Affairs, and Fogarty International Center sponsored a conference on hepatocellular carcinoma on April 1-3, 2004 to discuss the screening, diagnosis, and management of this type of cancer. You can view the agenda as well as a list of speakers by <a href='http://www.niddk.nih.gov/fund/other/hepato_carc/liver_cancer.pdf ' target='_blank'>clicking here</a>.","resourceClassificationName":"News & Events","resourceClassificationSectionName":"Other Conferences"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/278354-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401920' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1553,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://cis.nci.nih.gov' target='_blank'>National Cancer Institute</a> (CIS)  provides the most current information on cancer for patients, health professionals, and the general public. You can reach them by calling toll-free at 1-800-422-6237 or by visiting their Web site. ","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1817,"resourceId":3010,"resourceName":"Fibrolamellar Tissue Repository","descriptionText":"The <a href='http://fibrolamellar.rockefeller.edu/' target='_blank'>Fibrolamellar Tissue Repository</a> is a tissue bank for fibrolamellar samples obtained during surgery. This repository is&nbsp;a resource for Rockefeller University and other approved academic institutions who are interested in performing scientific research that will improve the diagnosis, treatment, and understanding of this rare disease.","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:5015' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Fibrolamellar carcinoma. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Fibrolamellar carcinoma:<br />\r\n<a href='https://fibroregistry.org/about' target='_blank'>Fibrolamellar Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":3759,"questionText":"What is fibrolamellar carcinoma?","answerText":"<span><strong>Fibrolamellar carcinoma (FLC)</strong> is a rare form of liver cancer which is generally diagnosed in adolescents and young adults (before age 40). Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003089.htm\" target=\"_blank\">malaise</a>) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified. FLC is typically treated with surgical <a href=\"http://www.cancer.gov/dictionary?CdrID=46565\" target=\"_blank\">resection</a>.[8729][8730][8731]</span>","dateModified":"2015-04-23T00:00:00"},"basicQuestions":[{"questionId":8621,"questionText":"What are the signs and symptoms of fibrolamellar hepatocellular carcinoma?","answerText":"Many people with early fibrolamellar carcinoma (FLC) have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Signs and symptoms may include:[8729][8730][14532][14537]\r\n<ul>\r\n    <li>Abdominal pain.</li>\r\n    <li>Loss of appetite.</li>\r\n    <li>Weight loss.</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003089.htm\" target=\"_blank\">Malaise</a>.</li>\r\n    <li>Jaundice.</li>\r\n    <li>Nausea and/or vomiting.</li>\r\n    <li>A palpable liver mass found on a physical exam.</li>\r\n</ul>\r\n<p>Other&nbsp;signs and symptoms that have been reported less commonly include:[8729][14532]</p>\r\n<ul>\r\n    <li><a href=\"https://www.dermnetnz.org/topics/trousseau-syndrome\" target=\"_blank\">Migratory thrombophlebitis</a> (Trousseau syndrome) or venous thrombosis.</li>\r\n    <li><a href=\"https://www.mayoclinic.org/diseases-conditions/gynecomastia/symptoms-causes/syc-20351793\" target=\"_blank\">Gynecomastia</a> (excessive breast tissue in males).</li>\r\n</ul>","dateModified":"2018-04-13T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":8729,"authors":"Michael A Choti, MD, MBA, FACS","articleTitle":"Fibrolamellar Carcinoma","bookWebsiteJournalTitle":"Medscape Reference","date":"August 2015","volume":"","pages":"","url":"http://emedicine.medscape.com/article/278354-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8730,"authors":"Lim II, Farber BA, LaQuaglia MP","articleTitle":"Advances in fibrolamellar hepatocellular carcinoma: a review","bookWebsiteJournalTitle":"Eur J Pediatr Surg","date":"December 2014","volume":"24(6)","pages":"461-466","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14532,"authors":"","articleTitle":"What is Fibrolamellar?","bookWebsiteJournalTitle":"Fibrolamellar Cancer Foundation","date":"","volume":"","pages":"","url":"http://fibrofoundation.org/learn/what-is-fibro/","dateAccessed":"2018-04-13T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14537,"authors":"Chagas AL, Kikuchi L, Herman P, et al","articleTitle":"Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases","bookWebsiteJournalTitle":"Clinics (Sao Paulo)","date":"January, 2016","volume":"70(3)","pages":"207-213","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26017653/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8622,"questionText":"What causes fibrolamellar carcinoma?","answerText":"The exact underlying cause of fibrolamellar carcinoma (FLC) is poorly understood. Other forms of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000280.htm\" target=\"_blank\">liver cancer</a> are often associated with liver cirrhosis (scarring of the liver) which may be caused by alcohol abuse; <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000816.htm\" target=\"_blank\">autoimmune diseases</a> of the liver; <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000279.htm\" target=\"_blank\">Hepatitis B</a> or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000284.htm\" target=\"_blank\">C</a> viral infections; <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002312.htm\" target=\"_blank\">chronic</a> inflammation of the liver; and/or <a href=\"http://rarediseases.info.nih.gov/gard/10746/hemochromatosis/resources/1\" target=\"_blank\">hemochromatosis</a>. However, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified.[8729][8730][8731]<br />\r\n<br />\r\nRecent research suggests that a <a href=\"https://www.genome.gov/glossary/index.cfm?id=45\" target=\"_blank\">deletion</a> on <a href=\"http://ghr.nlm.nih.gov/chromosome/19\" target=\"_blank\">chromosome 19</a>&nbsp;may play a key role in the formation of FLC.[8743] This deletion is called a \"<a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=46586\" target=\"_blank\">somatic mutation</a>\" since it is only present in the cells of the liver. Somatic mutations accumulate during a person's lifetime and are not inherited or passed on to future generations.","dateModified":"2015-04-22T20:04:00","resourceClassificationName":"Cause","references":[{"referenceId":8729,"authors":"Michael A Choti, MD, MBA, FACS","articleTitle":"Fibrolamellar Carcinoma","bookWebsiteJournalTitle":"Medscape Reference","date":"August 2015","volume":"","pages":"","url":"http://emedicine.medscape.com/article/278354-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8730,"authors":"Lim II, Farber BA, LaQuaglia MP","articleTitle":"Advances in fibrolamellar hepatocellular carcinoma: a review","bookWebsiteJournalTitle":"Eur J Pediatr Surg","date":"December 2014","volume":"24(6)","pages":"461-466","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8731,"authors":"Arief Suriawinata, MD","articleTitle":"Pathology of malignant liver tumors","bookWebsiteJournalTitle":"UpToDate","date":"November 2014","volume":"","pages":"","url":"","dateAccessed":"2015-04-22T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8743,"authors":"Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, Gleason CE, Murphy JM, Rosenberg BR, Teegan L, Takacs CN, Botero S, Belote R, Germer S, Emde AK, Vacic V, Bhanot U, LaQuaglia MP, Simon SM","articleTitle":"Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma","bookWebsiteJournalTitle":"Science","date":"February 2014","volume":"343(6174)","pages":"1010-1014","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8623,"questionText":"How is fibrolamellar carcinoma diagnosed?","answerText":"If fibrolamellar carcinoma (FLC) is suspected based on the presence of certain <a href=\"http://rarediseases.info.nih.gov/gard/9396/fibrolamellar-hepatocellular-carcinoma/resources/9\" target=\"_blank\">signs and symptoms</a>, imaging studies such as <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003777.htm\" target=\"_blank\">ultrasound</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003796.htm\" target=\"_blank\">MRI scan</a> and/or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003789.htm\" target=\"_blank\">CT scan</a> are typically recommended for diagnosis and <a href=\"http://www.cancer.gov/dictionary?CdrID=46597\" target=\"_blank\">staging</a>. Unlike other forms of liver cancer, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003573.htm\" id=\"anch_30\" target=\"_blank\">serum alpha fetoprotein</a> is typically not elevated in FLC.[8729][8730]<br />\r\n<br />\r\n<a href=\"http://emedicine.medscape.com/article/278354-workup#showall\" target=\"_blank\">Medscape Reference's</a> Web site offers more specific information on the diagnosis of FLC. Please click on the link to access this resource.","dateModified":"2015-04-22T20:30:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":8729,"authors":"Michael A Choti, MD, MBA, FACS","articleTitle":"Fibrolamellar Carcinoma","bookWebsiteJournalTitle":"Medscape Reference","date":"August 2015","volume":"","pages":"","url":"http://emedicine.medscape.com/article/278354-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8730,"authors":"Lim II, Farber BA, LaQuaglia MP","articleTitle":"Advances in fibrolamellar hepatocellular carcinoma: a review","bookWebsiteJournalTitle":"Eur J Pediatr Surg","date":"December 2014","volume":"24(6)","pages":"461-466","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8635,"questionText":"How might fibrolamellar carcinoma be treated?","answerText":"The standard treatment for fibrolamellar carcinoma (FLC) is surgical <a href=\"http://www.cancer.gov/dictionary?CdrID=46565\" target=\"_blank\">resection</a>. Due to the rarity of the condition, there is limited information to support the use of other treatment options and there is no standard&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">chemotherapy</a> regimen. However, other treatments may be considered&nbsp;if surgical resection isn't an&nbsp;option. For example,&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003006.htm\" target=\"_blank\">liver transplantation</a>&nbsp;may be considered in patients who are not candidates for partial resection (removing a portion of the liver).[8729][8730]<br />\r\n<br />\r\n<a href=\"http://emedicine.medscape.com/article/278354-treatment#showall\" target=\"_blank\">Medscape Reference's</a> Web site offers more specific information on the treatment and management of FLC. Please click the link to access this resource.&nbsp;","dateModified":"2015-04-23T13:07:00","resourceClassificationName":"Treatment","references":[{"referenceId":8729,"authors":"Michael A Choti, MD, MBA, FACS","articleTitle":"Fibrolamellar Carcinoma","bookWebsiteJournalTitle":"Medscape Reference","date":"August 2015","volume":"","pages":"","url":"http://emedicine.medscape.com/article/278354-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8730,"authors":"Lim II, Farber BA, LaQuaglia MP","articleTitle":"Advances in fibrolamellar hepatocellular carcinoma: a review","bookWebsiteJournalTitle":"Eur J Pediatr Surg","date":"December 2014","volume":"24(6)","pages":"461-466","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8636,"questionText":"What is the long-term outlook for people with fibrolamellar carcinoma?","answerText":"The long-term outlook (prognosis) for people with fibrolamellar carcinoma (FLC) is generally better than other forms of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000280.htm\" target=\"_blank\">liver cancer</a>, particularly when treated with surgical <a href=\"http://www.cancer.gov/dictionary?CdrID=46565\" target=\"_blank\">resection</a>.[8730][8729] In fact, reported 5-year survival rates range from 51 to 70% following liver resection.[8744][8745][8746][8730] <br />\r\n<br />\r\nUnfortunately, the prognosis is less favorable in people with unresectable disease. The median survival of these patients is approximately 14 months.[8729]","dateModified":"2015-04-23T13:26:00","resourceClassificationName":"Prognosis","references":[{"referenceId":8729,"authors":"Michael A Choti, MD, MBA, FACS","articleTitle":"Fibrolamellar Carcinoma","bookWebsiteJournalTitle":"Medscape Reference","date":"August 2015","volume":"","pages":"","url":"http://emedicine.medscape.com/article/278354-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8730,"authors":"Lim II, Farber BA, LaQuaglia MP","articleTitle":"Advances in fibrolamellar hepatocellular carcinoma: a review","bookWebsiteJournalTitle":"Eur J Pediatr Surg","date":"December 2014","volume":"24(6)","pages":"461-466","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8744,"authors":"Darcy DG, Malek MM, Kobos R, Klimstra DS, DeMatteo R, La Quaglia MP","articleTitle":"Prognostic factors in fibrolamellar hepatocellular carcinoma in young people","bookWebsiteJournalTitle":"J Pediatr Surg","date":"Jan 2015","volume":"50(1)","pages":"153-156","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8745,"authors":"Mavros MN, Mayo SC, Hyder O, Pawlik TM","articleTitle":"A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma","bookWebsiteJournalTitle":"J Am Coll Surg","date":"December 2012","volume":"215(6)","pages":"820-830","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8746,"authors":"Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF","articleTitle":"Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database","bookWebsiteJournalTitle":"United European Gastroenterol J. 2013 Oct;1(5):351-7","date":"October 2013","volume":"1(5)","pages":"351-7","url":"","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":6608,"relatedDiseaseName":"Primary liver cancer","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Fibrolamellar_carcinoma"}